Anti–amyloid β autoantibodies in cerebral amyloid angiopathy–related inflammation: Implications for amyloid‐modifying therapies

Cerebral amyloid angiopathy–related inflammation (CAA‐ri) is characterized by vasogenic edema and multiple cortical/subcortical microbleeds, sharing several aspects with the recently defined amyloid‐related imaging abnormalities (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies. Herein, we investigated the role of anti–amyloid β (Aβ) autoantibodies in the acute and remission phases of CAA‐ri.

[1]  S. Love,et al.  Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. , 2005, Brain : a journal of neurology.

[2]  A. Erbetta,et al.  Case 159: cerebral amyloid angiopathy-related inflammation. , 2010, Radiology.

[3]  B. Hyman,et al.  Autoantibodies to amyloid‐β and Alzheimer's disease , 2001, Annals of neurology.

[4]  W. Stummer,et al.  CD4(+) T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid β-related angiitis. , 2012, Archives of neurology.

[5]  S. Greenberg,et al.  Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston Criteria , 2003, Current atherosclerosis reports.

[6]  I. Mook‐Jung,et al.  Serum Anti-Amyloid-β Antibodies and Alzheimer's Disease in Elderly Korean Patients , 2007, The Journal of international medical research.

[7]  Eric E. Smith,et al.  Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston Criteria , 2003, Current atherosclerosis reports.

[8]  C. Ferrarese,et al.  Increased Soluble APPα, Abeta 1-42, and Anti-Abeta 1-42 Antibodies in Plasma From Down Syndrome Patients , 2010, Alzheimer disease and associated disorders.

[9]  M. Uchino,et al.  Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature , 2011, Journal of Neuroinflammation.

[10]  M. Frosch,et al.  Course of cerebral amyloid angiopathy–related inflammation , 2007, Neurology.

[11]  B. Croisile,et al.  Immune response to Aβ-peptides in peripheral blood from patients with Alzheimer's disease and control subjects , 2004, Neuroscience Letters.

[12]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[13]  M. Masserini,et al.  Aβ42 production in brain capillary endothelial cells after oxygen and glucose deprivation , 2012, Molecular and Cellular Neuroscience.

[14]  M. Staufenbiel,et al.  Cerebral hemorrhage after passive anti-Abeta immunotherapy. , 2002, Science.

[15]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[16]  N. Relkin,et al.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.

[17]  S. Love,et al.  Aβ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy , 2005 .

[18]  I. Appollonio,et al.  Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1–42 antibodies in Alzheimer's disease patients , 2010, Neuroscience Letters.

[19]  C. Holmes,et al.  Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis , 2010, Acta Neuropathologica.

[20]  M. Frosch,et al.  Clinical manifestations of cerebral amyloid angiopathy–related inflammation , 2004, Annals of neurology.

[21]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[22]  Nick C Fox,et al.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.

[23]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[24]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[25]  R. Barbour,et al.  Immunotherapy Reduces Vascular Amyloid-β in PDAPP Mice , 2008, The Journal of Neuroscience.

[26]  Keith A. Johnson,et al.  Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy , 2012, Neurology.

[27]  F. Barkhof,et al.  Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. , 2012, Archives of neurology.

[28]  S. Lehmann,et al.  Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria , 2012, Journal of Neurology.

[29]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[30]  B. Borroni,et al.  Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease , 2012, Neurobiology of Aging.

[31]  Lucie Yang,et al.  Brain amyloid imaging--FDA approval of florbetapir F18 injection. , 2012, The New England journal of medicine.

[32]  B. Synek,et al.  Cerebral amyloid angiopathy related inflammation: three case reports and a review , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  W. Oertel,et al.  Reduced levels of amyloid β-peptide antibody in Alzheimer disease , 2001, Neurology.

[34]  F. Tagliavini,et al.  Anti-Aβ autoantibodies in the CSF of a patient with CAA-related inflammation: A case report , 2011, Neurology.

[35]  A. Falini,et al.  Cerebral Amyloid Angiopathy-Related Inflammation: An Emerging Disease , 2011, The neuroradiology journal.

[36]  Charles D. Smith,et al.  Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity , 2007, NeuroMolecular Medicine.

[37]  K. Blennow,et al.  Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[38]  A. Maggi,et al.  Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. , 2010, Atherosclerosis.